Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.62 SEK | +5.22% | +7.82% | +16.87% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.03M | Sales 2025 * | 343M 31.55M | Capitalization | 1.93B 178M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.68M | Net income 2025 * | -712M -65.56M | EV / Sales 2024 * | 10.1 x |
Net Debt 2024 * | 474M 43.64M | Net Debt 2025 * | 733M 67.53M | EV / Sales 2025 * | 7.78 x |
P/E ratio 2024 * |
-2.66
x | P/E ratio 2025 * |
-3.15
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +5.22% | ||
1 week | +7.82% | ||
Current month | +5.81% | ||
1 month | +2.41% | ||
3 months | -16.34% | ||
6 months | +18.04% | ||
Current year | +16.87% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 30.62 | +5.22% | 181,265 |
24-05-07 | 29.1 | -2.28% | 139,243 |
24-05-06 | 29.78 | +0.13% | 181,130 |
24-05-03 | 29.74 | +4.72% | 208,900 |
24-05-02 | 28.4 | -1.87% | 125,328 |
Delayed Quote Nasdaq Stockholm, May 08, 2024 at 06:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.87% | 178M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- HNSA Stock